Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation
· seekingalpha.com
Seaport Therapeutics: Glyph platform de-risks prodrug delivery; BUOY-1 MDD data H1 2027, GAD Phase 2a H2 2026. Click here to read my analysis.
Seaport Therapeutics ( SPTX ) does not pursue the traditional biotech model of developing an all-new biological mechanism and years later testing whether it wil...